InfertilityPhase 1NCT00730496
Injection of Day 2 Embryo Culture Supernatant Into the Uterine Cavity Didn't Improve Implantation and Pregnancy Rates
A Phase 1 study testing uterine cavity injection of day 2 embryo culture supernatant in people with Infertility and In Vitro Fertilization, run by Shen-Zhen City Maternity and Child Healthcare Hospital at 1 site in China.
Trial summary
Forty-five infertile women undergoing in vitro fertilization treatment were managed by uterine cavity injection of day 2 embryo culture supernatant before day 3 embryo transfer. No statistically significant differences were found in implantation and pregnancy rates when compared with control group. Read more about this study
- Who is it for?
- Ages 23 to 39 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Infertility, In Vitro Fertilization
- What is being tested?
- uterine cavity injection of day 2 embryo culture supernatant
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 1 siteChina
- Study dates
- Jan 2008to Jul 2008
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 23 to 39 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- The participants were only those women who were first going to undergo IVF or ICSI treatment.
Who cannot join
- The women who were treated with natural cycle IVF or had no appropriate embryo for ET were excluded.
Trial locations and contacts
1 site in 1 country.
China1 site
Department of Reproductive Centre, Shen-Zhen Maternity and Child Healthcare Hospital
Shenzhen, Guangdong, 518048
About this study
Official title: Injection of Day 2 Embryo Culture Supernatant Into the Uterine Cavity Didn't Improve Implantation and Pregnancy Rates of Day 3 Embryo Transfer: a Randomized Clinical Trial in Patients Who Underwent in Vitro Fertilization- Embryo Transfer.
Forty-five infertile women undergoing in vitro fertilization treatment were managed by uterine cavity injection of day 2 embryo culture supernatant before day 3 embryo transfer. No statistically significant differences were found in implantation and pregnancy rates when compared with control group.
Read the detailed description
Study design and sample size This was a randomized clinical trial involving ninety patients who were undergoing conventional IVF or intracytoplasmic sperm injection (ICSI) treatment at our Reproductive Medical Center. The subjects were recruited and studied for a period of 6 months between January and June 2008. The study was approved by the Ethics Committee of Shen-Zhen Maternity and Child Healthcare Hospital. Subjects all signed an informed consent form.
According to the guideline made by the Ethics Committee of Shen-Zhen Maternity and Child Healthcare Hospital, we had better accomplish the study within six months. We calculated that, in our center, a sample size of 100 or more subjects would need to be recruited over about a 6 months period. We ended up with 90 patients in this study.
Subject Ninety infertile women, aged 23-39 years, with an infertile duration of 3-8 years, were enrolled from our infertility treatment clinic between January and June 2008. The selection criteria for participants were only those women who were first going to undergo IVF or ICSI treatment. Women who were treated with natural cycle IVF or had no appropriate embryo for ET were excluded. The infertility factors were identified as the following: tubal (n=54), unexplained (n=3), male n=22), endometriosis (n=9), others (n=2). The selection and enrollment for each subject was decided by three same physicians. All subjects were informed that this procedure was a new technique, and that its effectiveness has not been confirmed, although an optimal outcome in patients with blastocyst transfer was obtained by using this technique for the same purpose (6). During the selection procedure, four eligible subjects opted not to participate when counseled about the uncertain of effectiveness, and other two subjects declined to randomize. Finally, 90 eligible patients were enrolled.
Randomization First, ninety random numbers generated by means of computer were randomly divided into study group and control group. Then, all subjects in an enrolled date order were arranged according to the sequence of random numbers. So, ninety subjects were randomly divided into the study group and control group. The random allocation sequence was concealed in a closed and dark-colored envelope until the day of oocyte pick-up. Randomization occurred after patients agreed to participate in the study (Figure 1). All women of two groups underwent a conventional IVF or ICSI procedure, but in study group, the patients were added with a uterine cavity injection of day 2 embryo culture supernatant. The IVF or ICSI procedure was performed by same physicians and laboratory technicians. The treating sequence of subjects was as same as the enrolling sequence. The study was not blinded, because the patients as well as the clinicians were aware of the study content.
IVF or ISCI procedure and injection technique of embryo culture supernatant Controlled ovarian hyperstimulation was performed using a variety of protocols, as previously published elsewhere (8). A down-regulation of the pituitary was realized during triptorelin (Triptorelin Acetate Injection, Ferring, Germany) administration S.C., 0.1 mg/d×7, started from day 21 of the previous cycles. Ovarian stimulation started from day 3 of stimulated cycle by using recombinant follicle stimulating hormone (rFSH, Gonal-F, Serono, Switzerland), 225-300IU daily S.C.. The follicle development was monitored by transvaginal ultrasound scan (TVS). 250ug of HCG (Ovitrelle; Serono, Madrid) was administered by I.M. when one to two leading follicle(s) reached a mean diameter of 18 mm. In general, transvaginal oocyte retrieval was performed after 36 h of HCG injection.
The media used for embryo culture was IVF-60. Briefly, after oocyte retrieval (day 0), cumulus-enclosed oocytes were incubated in IVF-60. Semen was prepared with a 45-90 discontinuous gradient. The resulting pellet was washed in IVF-60. For normal IVF, 100,000 to 150,000 sperm/100ul were used for each oocyte. The maturation stage of oocyte was assessed for IVF 15-18 hour after insemination (day 1). Cumulus and corona cells were removed using drawn pipettes. When ICSI was performed, oocytes were denuded with HYASE. Each mature oocyte was placed in a 6-ul droplet of GAMETE-20. The partner's sperm was placed in a 6-ul droplet of ICSI-100. All droplets were overlaid with OVOIL. ICSI was performed using a inverted microscope with RI micromanipulators (INTEGRA Micromanipulation System, Research Instruments, UK). The CO2 incubators (Forma, USA) with 6% CO2 gas were used for embryo incubation. An embryo scoring system based on cleavage rate and morphologic features was used for the evaluation of embryo quality, as previously described elsewhere (9). Briefly, grade 1 is the best score and grade 5 is the worst. For example, a grade 1 embryo has blastomeres of equal size with no cytoplasmic fragmentation. A grade 2 embryo has symmetric blastomeres, but a small degree of cytoplasmic fragmentation involving ≤10% of the embryo's surface. Grades 3 through 5 demonstrate progressive embryo cytoplasmic fragmentation and variable cell symmetry.
On the day 2, the embryos were translated from the old dish to a new dish with fresh media and cultured continuously. In study group, the embryo culture supernatant at the old dish were aspirated by using embryo transfer catheter (COOK-5000, Australia) and injected into the patient's uterine cavity. ET was performed on the third day of embryo culture. Two to three embryos were selected to transfer for each woman. The number of embryos selected for transfer was based on morphologic criteria and some additional factors, such as duration and cause of infertility and age of the patient. Pregnancy was determined by carry out a urine pregnancy test after 14 days of ET. The embryo implantation, the number of gestational sacs, and embryo heart pulsation were determined by TVS in the seventh week of pregnancy. Except the day 2 embryo culture supernatant injection, all of the above-mentioned clinical and laboratory procedures were identical between the study group and control group.
Statistical analysis Baseline characteristics of the patients were expressed as mean ±standard deviation or frequencies and proportion (%). The pregnancy and implantation rates were calculated based on the cases of pregnancy and number of gestational sacs. A Chi-Square Test was used to compare the implantation and conception proportions between two groups. The Statistics Package for Social Science (SPSS 13.0; SPSS Inc.) was used for statistical analyses. Statistical significance was set at P<0.05.
- Conditions
- Infertility, In Vitro Fertilization
- Being tested
- uterine cavity injection of day 2 embryo culture supernatant
- Keywords
- Embryo culture supernatant, injection, embryo transfer, embryo implantation rate
- Medical subject headings
- Infertility
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
uterine cavity injection of day 2 embryo culture supernatantProcedure or surgery
On the day 2, the embryos were translated from the old dish to a new dish with fresh media and cultured continuously. In study group, the embryo culture supernatant at the old dish were aspirated by using embryo transfer catheter (COOK-5000, Australia) and injected into the patient's uterine cavity. But in the control group, this intervention was not done. Conventional ET was performed on the third day of embryo culture for both groups.
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | the study group, 45 women Receives: Procedure: uterine cavity injection of day 2 embryo culture supernatant |
| 2 | No intervention | the control group, 45 women |
What is being measured
The primary outcome is the main question the study is designed to answer.
The clinical pregnancy rate and embryo implantation rate.
Measured: two months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Aug 2008 (estimated)
- Study startJan 2008
- Primary completionJul 2008
- Study completionJul 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for InfertilityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- Shen-Zhen City Maternity and Child Healthcare Hospital
- Sponsor type
- University, hospital or other
- Investigators
- Wen-Jie Zhu, M.D, Study chair, Shenzhen Maternity & Child Healthcare Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00730496
- Sponsor's protocol ID
- 200803889
- Status last verified
- Aug 2008
- First submitted
- 31 Jul 2008
- Last updated
- 5 Nov 2010
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Injection of Day 2 Embryo Culture Supernatant Into the Uterine Cavity Didn't Improve Implantation and Pregnancy Rates of Day 3 Embryo Transfer: a Randomized Clinical Trial in Patients Who Underwent in Vitro Fertilization- Embryo Transfer.
- ClinicalTrials.gov ID
- NCT00730496
- Acronym / sponsor ID
- 200803889
- Conditions
- Infertility, In Vitro Fertilization
- Keywords
- Embryo culture supernatant, injection, embryo transfer, embryo implantation rate
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- Shen-Zhen City Maternity and Child Healthcare HospitalUniversity, hospital or other
- Study start
- Jan 2008
- Primary completion
- Jul 2008 (actual)
- Study completion
- Jul 2008 (actual)
- First posted
- 8 Aug 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Forty-five infertile women undergoing in vitro fertilization treatment were managed by uterine cavity injection of day 2 embryo culture supernatant before day 3 embryo transfer. No statistically significant differences were found in implantation and pregnancy rates when compared with control group.
Detailed description
Study design and sample size This was a randomized clinical trial involving ninety patients who were undergoing conventional IVF or intracytoplasmic sperm injection (ICSI) treatment at our Reproductive Medical Center. The subjects were recruited and studied for a period of 6 months between January and June 2008. The study was approved by the Ethics Committee of Shen-Zhen Maternity and Child Healthcare Hospital. Subjects all signed an informed consent form.
According to the guideline made by the Ethics Committee of Shen-Zhen Maternity and Child Healthcare Hospital, we had better accomplish the study within six months. We calculated that, in our center, a sample size of 100 or more subjects would need to be recruited over about a 6 months period. We ended up with 90 patients in this study.
Subject Ninety infertile women, aged 23-39 years, with an infertile duration of 3-8 years, were enrolled from our infertility treatment clinic between January and June 2008. The selection criteria for participants were only those women who were first going to undergo IVF or ICSI treatment. Women who were treated with natural cycle IVF or had no appropriate embryo for ET were excluded. The infertility factors were identified as the following: tubal (n=54), unexplained (n=3), male n=22), endometriosis (n=9), others (n=2). The selection and enrollment for each subject was decided by three same physicians. All subjects were informed that this procedure was a new technique, and that its effectiveness has not been confirmed, although an optimal outcome in patients with blastocyst transfer was obtained by using this technique for the same purpose (6). During the selection procedure, four eligible subjects opted not to participate when counseled about the uncertain of effectiveness, and other two subjects declined to randomize. Finally, 90 eligible patients were enrolled.
Randomization First, ninety random numbers generated by means of computer were randomly divided into study group and control group. Then, all subjects in an enrolled date order were arranged according to the sequence of random numbers. So, ninety subjects were randomly divided into the study group and control group. The random allocation sequence was concealed in a closed and dark-colored envelope until the day of oocyte pick-up. Randomization occurred after patients agreed to participate in the study (Figure 1). All women of two groups underwent a conventional IVF or ICSI procedure, but in study group, the patients were added with a uterine cavity injection of day 2 embryo culture supernatant. The IVF or ICSI procedure was performed by same physicians and laboratory technicians. The treating sequence of subjects was as same as the enrolling sequence. The study was not blinded, because the patients as well as the clinicians were aware of the study content.
IVF or ISCI procedure and injection technique of embryo culture supernatant Controlled ovarian hyperstimulation was performed using a variety of protocols, as previously published elsewhere (8). A down-regulation of the pituitary was realized during triptorelin (Triptorelin Acetate Injection, Ferring, Germany) administration S.C., 0.1 mg/d×7, started from day 21 of the previous cycles. Ovarian stimulation started from day 3 of stimulated cycle by using recombinant follicle stimulating hormone (rFSH, Gonal-F, Serono, Switzerland), 225-300IU daily S.C.. The follicle development was monitored by transvaginal ultrasound scan (TVS). 250ug of HCG (Ovitrelle; Serono, Madrid) was administered by I.M. when one to two leading follicle(s) reached a mean diameter of 18 mm. In general, transvaginal oocyte retrieval was performed after 36 h of HCG injection.
The media used for embryo culture was IVF-60. Briefly, after oocyte retrieval (day 0), cumulus-enclosed oocytes were incubated in IVF-60. Semen was prepared with a 45-90 discontinuous gradient. The resulting pellet was washed in IVF-60. For normal IVF, 100,000 to 150,000 sperm/100ul were used for each oocyte. The maturation stage of oocyte was assessed for IVF 15-18 hour after insemination (day 1). Cumulus and corona cells were removed using drawn pipettes. When ICSI was performed, oocytes were denuded with HYASE. Each mature oocyte was placed in a 6-ul droplet of GAMETE-20. The partner's sperm was placed in a 6-ul droplet of ICSI-100. All droplets were overlaid with OVOIL. ICSI was performed using a inverted microscope with RI micromanipulators (INTEGRA Micromanipulation System, Research Instruments, UK). The CO2 incubators (Forma, USA) with 6% CO2 gas were used for embryo incubation. An embryo scoring system based on cleavage rate and morphologic features was used for the evaluation of embryo quality, as previously described elsewhere (9). Briefly, grade 1 is the best score and grade 5 is the worst. For example, a grade 1 embryo has blastomeres of equal size with no cytoplasmic fragmentation. A grade 2 embryo has symmetric blastomeres, but a small degree of cytoplasmic fragmentation involving ≤10% of the embryo's surface. Grades 3 through 5 demonstrate progressive embryo cytoplasmic fragmentation and variable cell symmetry.
On the day 2, the embryos were translated from the old dish to a new dish with fresh media and cultured continuously. In study group, the embryo culture supernatant at the old dish were aspirated by using embryo transfer catheter (COOK-5000, Australia) and injected into the patient's uterine cavity. ET was performed on the third day of embryo culture. Two to three embryos were selected to transfer for each woman. The number of embryos selected for transfer was based on morphologic criteria and some additional factors, such as duration and cause of infertility and age of the patient. Pregnancy was determined by carry out a urine pregnancy test after 14 days of ET. The embryo implantation, the number of gestational sacs, and embryo heart pulsation were determined by TVS in the seventh week of pregnancy. Except the day 2 embryo culture supernatant injection, all of the above-mentioned clinical and laboratory procedures were identical between the study group and control group.
Statistical analysis Baseline characteristics of the patients were expressed as mean ±standard deviation or frequencies and proportion (%). The pregnancy and implantation rates were calculated based on the cases of pregnancy and number of gestational sacs. A Chi-Square Test was used to compare the implantation and conception proportions between two groups. The Statistics Package for Social Science (SPSS 13.0; SPSS Inc.) was used for statistical analyses. Statistical significance was set at P<0.05.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Procedure: uterine cavity injection of day 2 embryo culture supernatantthe study group, 45 women |
| 2 | No intervention | –the control group, 45 women |
Who may qualify
- Ages
- 23 to 39 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- The participants were only those women who were first going to undergo IVF or ICSI treatment.
Key exclusion criteria (1 listed)
- The women who were treated with natural cycle IVF or had no appropriate embryo for ET were excluded.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| uterine cavity injection of day 2 embryo culture supernatantOn the day 2, the embryos were translated from the old dish to a new dish with fresh media and cultured continuously. In study group, the embryo culture supernatant at the old dish were aspirated by using embryo transfer catheter (COOK-5000, Australia) and injected into the patient's uterine cavity. But in the control group, this intervention was not done. Conventional ET was performed on the third day of embryo culture for both groups. | Procedure or surgery | 1 |
Primary outcome
The clinical pregnancy rate and embryo implantation rate.
Time frame: two months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2010.
Related trials for Infertility
RecruitingObservational study
International Pilot Study for Dual Non-invasive Assesment of Embryo Development
Infertility
Active, not recruitingObservational study
Retrieval of Sperm From Men With Azoospermia Using Ultrasound-guided Rete Testis Aspiration
Azoospermia, Nonobstructive, Infertility, Male
Not yet recruiting
Spinery Basivertebral Nerve Ablation for Vertebrogenic Chronic Low Back Pain
Low Back Pain, Chronic Low Back Pain (CLBP)
RecruitingObservational study
Impact of Infertility on the Sexual Sphere in Couples Undergoing Assisted Reproduction
Sexual Health Quality of Life, Infertile Patients
RecruitingObservational study
Pilot Study of Discarded Blastocysts
Infertility (IVF Patients)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Wen-Jie Zhu, M.D study chair
Shenzhen Maternity & Child Healthcare Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing uterine cavity injection of day 2 embryo culture supernatant in people with Infertility and In Vitro Fertilization, run by Shen-Zhen City Maternity and Child Healthcare Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Nov 2010. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The clinical pregnancy rate and embryo implantation rate. (time frame: two months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2010.